Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Novartis
Argus Health
Accenture
Merck
Cantor Fitzgerald
Mallinckrodt
Colorcon
Dow

Generated: October 21, 2017

DrugPatentWatch Database Preview

Angelini Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for ANGELINI PHARMA, and what generic alternatives to ANGELINI PHARMA drugs are available?

ANGELINI PHARMA has one approved drug.

There are three US patents protecting ANGELINI PHARMA drugs.

There are ninety-three patent family members on ANGELINI PHARMA drugs in thirty-three countries.

Summary for Applicant: Angelini Pharma

International Patents:93
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Angelini Pharma
OLEPTRO
trazodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022411-001Feb 2, 2010DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Angelini Pharma
OLEPTRO
trazodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022411-001Feb 2, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Angelini Pharma
OLEPTRO
trazodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022411-002Feb 2, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Angelini Pharma
OLEPTRO
trazodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022411-001Feb 2, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Angelini Pharma
OLEPTRO
trazodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022411-002Feb 2, 2010DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Angelini Pharma
OLEPTRO
trazodone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022411-002Feb 2, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ANGELINI PHARMA drugs

Drugname Dosage Strength Tradename Submissiondate
trazodone hydrochloride
Extended-release Tablets150 mg and 300 mg
OLEPTRO
10/18/2010

Non-Orange Book Patents for Angelini Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,314,236Trazodone and trazodone hydrochloride in purified form► Subscribe
8,414,919Sustained drug release composition► Subscribe
8,962,019Sustained drug release composition► Subscribe
9,439,866Trazodone composition for once a day administration► Subscribe
8,795,723Sustained drug release compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Angelini Pharma Drugs

Country Document Number Estimated Expiration
BrazilPI0615860► Subscribe
Australia2006308449► Subscribe
Australia2008285779► Subscribe
Argentina059682► Subscribe
Norway20026254► Subscribe
Argentina067773► Subscribe
Russian Federation2008113439► Subscribe
CroatiaP20140978► Subscribe
Canada2616416► Subscribe
New Zealand523644► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
McKinsey
Teva
Boehringer Ingelheim
Johnson and Johnson
US Army
Cerilliant
Federal Trade Commission
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot